 |
OnDose(R) Study Demonstrates Need for Improved Dosing Approach for Colorectal Cancer Patients
Jun 9, 2011
|
16.1 KB |
|
| |
SALT LAKE CITY, June 9, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in Clinical Colorectal Cancer entitled "Body Surface Area-based Dosing of 5-Fluoruracil Results in Extensive Inter-individual Variability in 5-Fluroruracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens" demonstrate...
|
|
Myriad's PROLARIS(R) Test Shown to Significantly Predict Prostate Cancer Outcome From Needle Biopsy Tissue
Jun 6, 2011
|
16.7 KB |
|
| |
SALT LAKE CITY, June 6, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort," was presented on Saturday, June 4, 2011 at the Ameri...
|
|
Myriad Genetics Completes Acquisition of Rules-Based Medicine
Jun 1, 2011
|
15.3 KB |
|
| |
SALT LAKE CITY and AUSTIN, Texas, June 1, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has completed the previously announced acquisition of Rules-Based Medicine (RBM) for approximately $80 million in cash.
Rules-Based Medicine is a leader in the discovery of novel biomarkers for its pharmaceutical an...
|
|
Myriad Genetics to Present at the Jefferies Global Healthcare Conference
May 24, 2011
|
21.3 KB |
|
| |
SALT LAKE CITY, May 24, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Mark Capone, President, Myriad Genetic Laboratories, Inc., is scheduled to present at the Jefferies Global Healthcare Conference, at 8:00 a.m. Eastern Time on June 7, 2011, at the Grand Hyatt New York Hotel in New York, New York.
The pr...
|
|
Myriad Genetics Announces Presentation of Prostate Cancer Study at American Society for Clinical Oncology Annual Meeting
May 18, 2011
|
22.5 KB |
|
| |
SALT LAKE CITY, May 18, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today the presentation of a study at the American Society of Clinical Oncology® (ASCO) Annual Meeting, including the complete results from a study titled, "Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer d...
|
|
Myriad Genetics Licenses Novel Technology From Chronix Biomedical
May 10, 2011
|
24.9 KB |
|
| |
SALT LAKE CITY, May 10, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement to license proprietary technology for the early detection of cancer from Chronix Biomedical of San Jose, California. Under the agreement, Myriad has rights in North America, South America, and Europe to commercialize ...
|
|
Myriad Genetics Reports Fiscal 2011 Third Quarter Results
May 3, 2011
|
30.2 KB |
|
| |
SALT LAKE CITY, May 3, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ending March 31, 2011. Revenue for the third fiscal quarter was $102.4 million, an increase of 13 percent over the $90.8 million reported in the third fiscal quarter of 2010. Operating income was $...
|
|
Myriad Genetics Announces Agreement to Acquire Rules-Based Medicine
Apr 27, 2011
|
24.5 KB |
|
| |
SALT LAKE CITY and AUSTIN, Texas, April 27, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics Inc. (Nasdaq:MYGN) today announced that it has entered into a definitive merger agreement to acquire privately-held Rules-Based Medicine (RBM) of Austin, Texas for $80 million in cash. The deal expands Myriad's research portfolio into new disease states, includin...
|
|
Myriad Genetics and BioMarin Pharmaceutical Inc. Enter Into Agreement
Apr 6, 2011
|
24.4 KB |
|
| |
SALT LAKE CITY, April 6, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with BioMarin Pharmaceutical Inc., a leading biopharmaceutical company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in BioMarin's Phase I/II clinical study of BMN 673, a novel PARP-inhibito...
|
|
Myriad Genetics to Announce Fiscal Third Quarter Financial Results on Tuesday, May 3, 2011
Apr 5, 2011
|
19.3 KB |
|
| |
SALT LAKE CITY, April 5, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter following the close of market on Tuesday, May 3, 2011.
The Company will also host a conference call on Tuesday, May 3, 2011 at 4:30 P.M. Eastern to review the financial resul...
|
|
Myriad Announces New $100 Million Share Repurchase Program
Mar 1, 2011
|
22.3 KB |
|
| |
SALT LAKE CITY, March 1, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that its Board of Directors has authorized a third $100 million stock repurchase program. In connection with this stock repurchase authorization, the Company has entered into an accelerated share repurchase (ASR) agreement with J.P. Morgan under wh...
|
|
Myriad Genetics to Present at the Citi Global Healthcare Conference
Feb 16, 2011
|
21.1 KB |
|
| |
SALT LAKE CITY, Feb. 16, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Citi Global Healthcare Conference, at 10:00 a.m. Eastern Time on March 2, 2011, at The Hilton New York Hotel in New York, New York.
The presentation will be available ...
|
|
Myriad's PROLARIS(TM) Test Shown to Significantly Predict Prostate Cancer Outcome
Feb 9, 2011
|
22.5 KB |
|
| |
SALT LAKE CITY, Feb. 9, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in Lancet Oncology shows the Company's 46-gene PROLARIS™ molecular diagnostic test significantly predicts prostate cancer outcome. The study demonstrated that a patient's cell cycle progression (CCP) score is a strong indicato...
|
|
Myriad Genetics Reports Fiscal 2011 Second Quarter Results
Jan 27, 2011
|
29.8 KB |
|
| |
SALT LAKE CITY, Jan. 27, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its second fiscal quarter ending December 31, 2010. Revenue for the second fiscal quarter was $100.4 million, an increase of 8 percent over the $92.8 million reported in the second fiscal quarter of 2010. Operating income was $38.6 mill...
|
|
Myriad Genetics to Report Fiscal 2011 Second Quarter Financial Results on January 27
Jan 10, 2011
|
18.9 KB |
|
| |
SALT LAKE CITY, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will release its financial results for its second fiscal quarter ended December 31, 2010, at the close of market on Thursday, January 27, 2011.
The Company will host a conference call on Thursday, January 27, at 4:30 p.m. Eastern t...
|
|
Myriad Genetics to Present at the 29th Annual J.P. Morgan Healthcare Conference
Dec 22, 2010
|
20.9 KB |
|
| |
SALT LAKE CITY, Dec. 22, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference, at 4:00 p.m. Pacific on January 12, 2011, at the Westin St. Francis Hotel in San Francisco, California.
The presentation...
|
|
Myriad Genetics Launches PANEXIA, New Predictive Test for Hereditary Pancreatic and Related Cancers
Dec 20, 2010
|
22.6 KB |
|
| |
SALT LAKE CITY, Dec. 20, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced the launch of PANEXIA™, a predictive medicine product for hereditary pancreatic and related cancers. PANEXIA is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. PANEX...
|
|
Newly Published Study Finds High Prevalence of BRCA Mutations in Breast Carcinoma in Situ (CIS)
Dec 14, 2010
|
24.9 KB |
|
| |
SALT LAKE CITY, Dec. 14, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that an article entitled "Prevalence of BRCA1 and BRCA2 Mutations In Women With Carcinoma In Situ of the Breast Referred for Genetic Testing" will appear in the December 2010 issue of the journal Cancer Prevention Research. The study demonstrated t...
|
|
Myriad Acquires Novel Technology From Melanoma Diagnostics
Dec 8, 2010
|
23.1 KB |
|
| |
SALT LAKE CITY, Dec. 8, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement to acquire proprietary technology for the diagnosis and prognosis of malignant melanoma using highly validated genetic markers from Melanoma Diagnostics, Inc. of Altadena, California. Under the agreement, Myriad has t...
|
|
Myriad Genetics Applauds Major Health Economic Study That Supports Broad Application of Genetic Testing for Hereditary Colon Cancer
Nov 29, 2010
|
25.0 KB |
|
| |
SALT LAKE CITY, Nov. 29, 2010 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today said results from a major health economics study in Cancer Prevention Research, a journal of the American Association for Cancer Research (AACR), found that screening for inherited gene mutations in the genes that cause a major colorectal cancer syndrome cal...
|
|
|
